Recent studies suggest LSR suppresses CD8+ T-cell activity in the tumor microenvironment (63), which may explain the enhanced efficacy in syngeneic models, where the ADC’s cytotoxic effects (via DM1) synergize with LSR mAb-mediated immune activation. The gene discussed is CD8A; the disease is neoplasm.